| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Targeted monoclonal antibodies improved therapeutic efficacy in some autoimmune diseases, but it is insufficient for complete inhibition.
Focused on experimental autoimmune encephalomyelitis (EAE), we demonstrated that sensitization of superior dominant peptide sustained remission by inducing CD69+CD103+ (DP) subset of regulatory T cells (Treg). DP-subset of Treg was the most potent one, and possessed multiple hybrid signatures corresponding to each phase of EAE, stabilized with retention of the IL6R expression low. DP-subset obtained high antigen-specificity within hybrid signatures and IL6Rlow fraction, which required proper antigen stimulation for their maintenance. By limiting to its own, sensitization of superior dominant peptide could suppress the reactivity to other encephalitogenic peptides tissue-specifically, unlike tolerance-induction that inhibited just peptide-specifically. Such suppression was available even under EAE-undeveloped condition and in EAE-established mice.
|
